Related Experiment Video
Updated: Jun 14, 2025
09:47
Interfacing 3D Engineered Neuronal Cultures to Micro-Electrode Arrays: An Innovative In Vitro Experimental Model
Published on: October 18, 2015
10.0K
Insights into Early Interactions on Innovative Developments with European Regulators
David W Uster1, Valentina Cordo'2, Emmanuel Cormier3
1European Medicines Agency (EMA), Amsterdam, The Netherlands. uster.dav@gmail.com.
Therapeutic Innovation & Regulatory Science
|August 30, 2024
Summary
The European Medicines Agency Innovation Task Force (ITF) briefing meetings foster medicine innovation. Analysis shows regulators provide guidance in 85% of responses, aiding early drug development.
Area of Science:
- Regulatory Science
- Pharmaceutical Innovation
- Drug Development
Background:
- The European Medicines Agency Innovation Task Force (ITF) facilitates early-stage drug development through briefing meetings.
- These meetings serve as a crucial contact point for medicine and technology developers to foster innovation.
Purpose of the Study:
- To analyze the pace of innovation and the effectiveness of ITF stakeholder interactions.
- To assess developer questions and European regulator feedback from 2021-2022 ITF briefing meetings.
Main Methods:
- Extraction and categorization of questions from ITF briefing meetings.
- Thematic analysis across the drug development lifecycle, including manufacturing, pre-clinical, and clinical aspects.
Main Results:
- Regulators provided initial guidance in 85% of responses.
- Concrete examples were given in 20% of answers, and further discussions were recommended in 22% of cases.
- Analysis identified key topics and the nature of regulatory feedback provided.
Conclusions:
- ITF briefing meetings are vital for fostering innovation in medicine development.
- The study highlights the content of discussions and regulatory feedback, identifying areas for enhancing early interactions.
- These interactions play a significant role in advancing novel therapeutics.
Related Concept Videos
01:28Preclinical Development: Overview
4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K
01:25Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
01:11Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
01:19Pharmacovigilance
789
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
789
01:03Drug Control Governance: Regulatory Bodies and Their Impact
146
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
146
01:26Drug Discovery: Overview
7.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.7K